Table 3.
Univariate and multivariate analyses of factors associated with overall survival
| Variables | Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95%CI | p value | HR | 95%CI | p value | |||
| Lower | Upper | Lower | Upper | |||||
| ENZ vs ABI | 1.280 | 0.873 | 1.884 | 0.205 | 1.105 | 0.810 | 1.507 | 0.529 |
| Metastasis vs non-metastasis | 1.200 | 0.835 | 1.719 | 0.328 | 1.412 | 1.011 | 1.970 | 0.043 |
| Gleason score ≥ 8 vs Gleason score < 8 | 0.810 | 0.566 | 1.148 | 0.232 | 1.004 | 0.731 | 1.379 | 0.981 |
| Age ≥ 75.6 (median) vs < 75.6 | 1.100 | 0.770 | 1.571 | 0.601 | 0.988 | 0.729 | 1.338 | 0.938 |
| DOC treatment vs non-DOC treatment | 2.070 | 1.410 | 3.045 | < 0.001 | 2.160 | 1.571 | 2.970 | < 0.001 |
| NLR > 3.02 vs ≤3.02 | 2.070 | 1.094 | 2.300 | 0.015 | 2.115 | 1.540 | 2.906 | < 0.001 |
| ALP > 274 (median) vs ≤274 | 1.580 | 1.295 | 2.760 | < 0.001 | 2.189 | 1.579 | 3.035 | < 0.001 |
| LDH > 220 (median) vs ≤220 | 1.790 | 1.234 | 2.597 | 0.002 | 2.284 | 1.647 | 3.168 | < 0.001 |
HR Hazard ratio, CI Confidential interval, ABI Abiraterone, ENZ Enzalutamide, DOC Docetaxel
NLR Neutrophil to lymphocyte ratio, ALP Alkaline phosphatase, LDH Lactate dehydrogenas